Maxim raised the firm’s price target on Nephros (NEPH) to $6 from $4.50 and keeps a Buy rating on the shares. The company’s Q2 results saw revenue, gross margins, and earnings all above consensus estimates, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEPH: